In vivo activation of tumor-specific cytotoxic T cells

Details In vivo activation of tumor-specific cytotoxic T cells In vivo activation of tumor-specific cytotoxic T cells

1999-03-26

2008-07-22

Foley, Shanon (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S009100, C424S185100, C424S194100, C530S300000, C514S002600

Reexamination Certificate

active

07402314

ABSTRACT:
The present invention relates to methods and compositions of activating cytotoxic T lymphocytes (CTLs) in vivo with specificity for particular antigenic peptides, and to methods and compositions of using activated CTLs in vivo for the treatment of a variety of disease conditions. In some preferred embodiments, the invention provides methods of employing a polypeptide of the amino acid sequence VMAGVGSPYV to specifically activating CTLs in subjects having a breast cancer overexpressing a Her-2/Neu protein, and methods of using the polypeptide to treat such subjects.

REFERENCES:
patent: 4950598 (1990-08-01), Engleman et al.
patent: 5112948 (1992-05-01), Jones
patent: 5292642 (1994-03-01), Jones
patent: 5434247 (1995-07-01), Jones
patent: 5679641 (1997-10-01), Melief et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 6419931 (2002-07-01), Vitiello et al.
patent: WO 93 24525 (1993-12-01), None
patent: WO 94 20127 (1994-02-01), None
patent: WO 94 20127 (1994-09-01), None
Yoshino, I et al, 1994, J Immunol, 152(5): 2393-400.
Stedman's medical dictionary, 25th ed, 1990, pp. 1652-1653.
White et al, 2001, Ann Rev Med, 52: 125-145.
Gu K et al, Cancer letters, Feb. 6, 1996,99(2): p185-9.
Costa MJ et al, American J Clin Pathol, 1995, v. 104, n. 6, p. 634-642.
Danova M et al, European journal of histochemistry, 1992, 36(3): p.279-88.
Sherman LA. Art. Rev. Immunol 18 (1-2): 47-54, 1998.
Boon, Adv. Cancer Res. 58:177-210, 1992.
Jura. Science, 278:1041-1042, 1997.
Jain, Science, 271:5-65, 1994.
Curti, Crit. Rev. Oncol/Hematol. 14:29-39, 1993.
Freshney, Cult. Animal Cells. A Manual of Basic Tech. Alan R. Liss, N.Y., p. 4, 1983.
Dermer, Bio/Technology , 12:320, 1994.
Di Fiore, et al.,Science 237: 178 (1987).
Dittmer, et al.,Nature Gen. 4: 42 (1993).
Falk, et al.,Nature 351: 290 (1991).
Harlow, et al.,Mol. Cell. Biol. 5: 1601 (1985).
Hinds, et al.,Cell Growth Diff. 1: 571 (1990).
Houbiers, et al.,Eur. J. Immunol. 23: 2072-2077 (1993).
Hunt, et al.,Science 255: 1261 (1992).
Ioannides, et al.,Cellular Immunol. 151: 225-234 (1993).
Ioannides, et al.,J. Immunol. 146: 1700 (1991).
Irwin, et al.,J. Exp. Med. 170: 1091 (1989).
Melief and Kast,Curr. Op. Immunol. 5: 709-713 (1993).
Vitiello, et al.,J. Exp. Med. 173: 1007-1015 (1991).
Winter, et al.,Cancer Res. 52: 4168-74 (1992).
Yoshino, et al.,J. Immunol. 152: 2393 (1994).
Guo, et al., “Different Length Peptides Bind to HLA-Aw68 Similarly at Their Ends But Bulge Out in the Middle”,Nature 360: 364-366 (1992).
Boon, “Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy”,Int. J. Cancer 54: 177-180 (1993).
Melief, et al., “Potential Immunogenicity of Oncogene and Tumor Suppressor Gene Products”,Curr. Opin. Immunol. 5: 709-713 (1993).
Houbiers, et al., “In Vitro Induction of Human Cytotoxic T Lymphocyte Responses Against Peptides of Mutant and Wild-Type p53”,Eur. J. Immunol. 23: 2072-2077 (1993).
Ruppert, et al., “Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules”,Cell 74: 929-937 (1993).
Nijman, et al., “p53, a Potential Target for Tumor-Directed T Cells”,Immunol. Lett. 40: 171-178 (1994).
Pietras, et al., “Antibody to HER-2
euReceptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells”,Oncogene 9: 1829-1838 (1994).
Tilkin, et al., “Primary Proliferative T Cell Response to Wild-Type p53 Protein in Patients with Breast Cancer”,Eur. J. Immunol. 25: 1765-1769 (1995).
Nijman, et al., “Characterization of Cytotoxic T Lymphocyte Epitopes of a Self-Protein, p53, and a Non-Self-Protein, Influenza Matrix: Relationship Between Major Histocompatibility Complex Peptide Binding Affinity and Immune Responsiveness to Peptides”,J. Immunotherapy 14: 121-126 (1993).
Spitler, “Cancer Vaccines: The Interferon Analogy”,Cancer Biotherapy 10: 1-3 (1995).
Ezzell, “Cancer “Vaccines”: An Idea Whose Time Has Come?”,J. NIH Res. 7: 46-49 (1995).
Allen, et al., “Identification of the T-Cell and Ia contact residues of a T-cell Antigenic Epitope”,Nature 327: 713-715 (1987).
Sette, et al., “Structural Characteristics of an Antigen Required for its Interaction with Ia and Recognition by T cells”,Nature 328: 395-399 (1987).
Deres, et al., “In Vivo Priming of Virus-Specific Cytotoxic T lymphocytes with Synthetic Lipopeptide Vaccine”,Nature 342: 561-564 (1989).
Vitiello, et al., “Analysis of the HLA-Restricted Influenza-Specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex”,J. Exp. Med. 173: 1007-1015 (1991).
Jardetzky, et al., “Identification of Self Peptides Bound to Purified HLA-B27”,Nature 353: 326-329 (1991).
Farouqi, et al., “Establishment of T-Lymphoid Cell Lines from Morroccan Patients with Tropical Spastic Paraparesis”,AIDS Research and Human Retroviruses 8: 1209-1213 (1992).
van der Bruggen, et al., “Molecular Definition of Tumor Antigens Recognized by T Lymphocytes”,Curr. Opin. Immunol. 4: 608-612 (1992).
Lane, “p53, Guardian of the Genome”,Nature 358: 15-16 (1992).
Ullrich, et al., “The p53 Tumor Suppressor Protein, a Modulator of Cell Proliferation”,J. Biol. Chem. 267: 15259-15262 (1992).
Hartwell, “Defects in a Cell Cycle Checkpoint May be Responsible for the Genomic Instability of Cancer Cells”,Cell 71: 543-546 (1992).
Epstein, et al., “Synthetic Phosphopeptide Immunogens Yield Activation-Specific Antibodies to the c-erbB-2 Receptor”,Proc. Natl. Acad. Sci. USA 89: 10435-10439 (1992).

Affiliated with

Also associated with

Rating

In vivo activation of tumor-specific cytotoxic T cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with In vivo activation of tumor-specific cytotoxic T cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vivo activation of tumor-specific cytotoxic T cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3963518